Radiopharmaceuticals Global Market Report 2026

Radiopharmaceuticals are medications that contain radioactive substances and are used for the diagnosis or treatment of diseases, including cancer. Also known as radioactive drugs, they are employed to identify specific illnesses or detect medical conditions. These medications can be administered to patients through various methods, such as injection, oral intake, or delivery into areas like the eye or bladder.

The primary types of radiopharmaceuticals include diagnostic, therapeutic, and others. Radiopharmaceutical therapeutics involve the delivery of radioactive atoms to targets associated with tumors. These agents are used across applications such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others, and are utilized by hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and other healthcare facilities.

Tariffs have influenced the radiopharmaceuticals market by increasing costs related to radioisotope imports, nuclear medicine equipment, and specialized transportation systems. Diagnostic and therapeutic radiopharmaceutical segments are particularly affected due to time-sensitive supply chains. North america and europe face operational challenges because of cross-border isotope dependency. However, tariffs are driving investments in domestic isotope production and regional cyclotron facilities. These efforts are improving supply reliability and supporting long-term market growth.

The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiopharmaceuticals market size has grown rapidly in recent years. It will grow from $7.3 billion in 2025 to $8.25 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to adoption of nuclear imaging technologies, growth in cancer diagnosis rates, availability of radioisotopes, hospital-based nuclear medicine expansion, regulatory approvals for diagnostic agents.

The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $13.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growth in precision oncology, rising demand for targeted radiotherapies, expansion of diagnostic imaging centers, investments in cyclotron infrastructure, technological advancements in isotope production. Major trends in the forecast period include rising use of radiopharmaceuticals in oncology, growth of theranostics applications, expansion of pet and spect imaging, increasing development of targeted radiotherapies, improved nuclear medicine infrastructure.

The growing prevalence of cancer and cardiovascular diseases is expected to increase demand for the radiopharmaceuticals market. Radiopharmaceuticals are gaining recognition as safe and effective therapeutic options compared with conventional medicines. They offer significant advantages to radiologists in the treatment of cancer and cardiovascular conditions due to benefits such as targeted therapy and precision treatment. Cancer is the second leading cause of death globally, accounting for approximately one in six deaths worldwide. For example, in April 2024, according to the International Agency for Research on Cancer (IARC), a France-based specialized agency, nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported worldwide in 2022. These figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the increasing incidence of cancer and cardiovascular diseases is expected to significantly boost demand for radiopharmaceuticals used in their treatment.

Major companies operating in the radiopharmaceuticals market are increasingly engaging in strategic partnerships to accelerate innovation and broaden access to advanced diagnostic and therapeutic solutions. These collaborations aim to strengthen radiopharmaceutical development, enhance regional manufacturing capabilities, and meet the rising demand for precision imaging and targeted therapies. For instance, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to jointly develop and manufacture new radiopharmaceuticals at a facility in Pittsburgh. This partnership is intended to expand access for patients and clinicians to advanced diagnostic and therapeutic agents that are not readily available in surrounding regions. Under the non-exclusive agreement, UPMC and PharmaLogic will convert experimental radiopharmaceuticals into clinically viable products, supporting broader commercialization and faster adoption of innovative nuclear medicine treatments.

In January 2024, Eli Lilly, a US-based pharmaceutical company, completed the acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to strengthen its position in the growing field of radioligand therapies, which offer promising advancements in cancer treatment. Point Biopharma specializes in radiopharmaceutical development, complementing Lilly's oncology portfolio and supporting efforts to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for multiple cancer types.

Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, UJV Rez, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacybapy-Monrol Nuclear Products, NTP Radioisotopes.

North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceuticals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses radiopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Diagnostic; Therapeutic
• 2) By Application: Oncology; Cardiology; Gastroenterology; Neuroendocrinology; Musculoskeletal; Respiratory; Nephrology; Other Applications
• 3) By End User: Hospitals And Ambulatory Surgical Centers; Diagnostic Centers; Cancer Research Institutes
• Subsegments:
• 1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals; Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
• 2) By Therapeutic: Alpha Emitters; Beta Emitters; Brachytherapy
• Companies Mentioned: Cardinal Health; Curium Pharma; Siemens Healthineers AG; Novartis AG; General Electric Company (GE); IBA Group; Bayer AG; Lantheus Medical Imaging Inc.; Bracco Imaging S.p.A.; Eckert & Ziegler; Nihon Medi-Physics Co. Ltd.; Fujifilm Corporation; ANSTO; Yantai Dongcheng Pharmaceutical Group Co. Ltd.; Bracco Imaging SpA.; Canon Inc.; China Isotope & Radiation Corporation (CIRC); Alliance Medical; Advanced Accelerator Applications; JSC Isotope; Pharm-Sintez; Synektik SA; Polatom; RadioMedic sro; UJV Rez; Actinium Pharmaceuticals Inc.; Alseres Pharmaceuticals Inc.; Avid Radiopharmaceuticals; Fusion Pharmaceuticals; Peregrine Pharmaceuticals Inc.; PETNET Solutions Inc.; Positron Corporation; Triad Isotopes Inc.; Telix Pharmaceuticals; Rosatom; Alliance Medical Group; Hologic Inc.; Segami Corporation; Eczacybapy-Monrol Nuclear Products; NTP Radioisotopes.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.